Why do drugs like Ozempic produce far greater and more lasting weight loss than older appetite suppressants? Scientists are beginning to uncover an unexpected answer in the brain.
Semaglutide, the active ingredient in Ozempic and other GLP-1 medications, may owe part of its remarkable weight loss effects to an unexpected group of brain cells. A new Yale study found that the drug activates neurons best known for driving hunger, challenging the idea that successful obesity treatments simply need to suppress the brain’s appetite signals.
These agouti-related peptide (AgRP) neurons sit in the hypothalamus, a brain region that helps regulate hunger, metabolism, and energy balance. They typically become more active when the body is running low on energy, encouraging eating and helping defend against further weight loss. For that reason, scientists have generally viewed them as an obstacle to losing weight.
Hunger Neurons Take a Surprising Role
Instead, Yale researchers found that sustained semaglutide treatment activated AgRP neurons in mice. When the scientists genetically removed the neurons or interfered with their function, semaglutide became less effective at maintaining weight loss under the conditions tested. The work suggests that these hunger-associated neurons can play a more complicated role in metabolism than previously recognized.
“This completely changes how we think about the mechanism involved in these medications and provides new insight into the biology underlying their long-term effects, opening an avenue for the development of more efficient drugs,” said Mateus d’Ávila, a Ph.D. candidate in neuroscience working in Tamas Horvath’s lab in the Department of Comparative Medicine at Yale School of Medicine (YSM) and first author of the study.
The study appears in Proceedings of the National Academy of Sciences (PNAS).
Why Appetite Suppression Is Not the Whole Story
Semaglutide belongs to a class of drugs that mimic the effects of glucagon-like peptide 1, or GLP-1, a hormone involved in blood sugar regulation, digestion, and appetite. GLP-1 therapies are now widely used for type 2 diabetes and obesity.
Their effectiveness has raised a basic biological question. Previous weight loss drugs could substantially reduce appetite, yet they generally did not produce the same magnitude of sustained weight loss seen with semaglutide.
That discrepancy suggested to the Yale team that something more than appetite suppression might be happening.
A common hypothesis was that GLP-1 treatment works partly by quieting neurons that encourage eating. But the specific contribution of AgRP neurons during prolonged treatment had not been directly established in living animals.
Testing How Semaglutide Changes the Brain
To investigate, the researchers treated mice with semaglutide while measuring changes in body weight, food consumption, metabolism, and energy expenditure. They also used genetic techniques to eliminate or reduce the activity of AgRP neurons and then examined how the animals responded to treatment.
The results went against the expected model. Semaglutide did not simply shut down these hunger neurons. Techniques including electrophysiology, molecular analysis, and electron microscopy indicated that the neurons became more active.
When AgRP neurons were removed or their function was reduced, semaglutide produced less sustained weight loss in female mice eating a standard diet. The researchers also found that nutritional conditions mattered. Under high-fat diet conditions, AgRP neurons were no longer required for the same weight loss response, suggesting that the brain circuits recruited by semaglutide may change depending on diet.
Rather than acting through one fixed pathway, semaglutide may engage different parts of the brain’s metabolic network depending on the body’s nutritional state.
AgRP Neurons and Metabolic Adaptation
The apparent contradiction begins to make more sense when AgRP neurons are viewed as regulators of energy balance rather than simple hunger switches.
The brain continuously monitors whether the body has enough energy available. When calorie intake falls, neural circuits can alter hunger, metabolism, and energy use in an effort to preserve body weight. AgRP neurons are a central part of that system and have long been studied for their role in feeding and metabolic regulation. Yale’s Horvath laboratory has investigated how these neurons respond to metabolic signals and how changes within the cells influence appetite and weight.
The new results suggest that semaglutide may take advantage of that circuitry rather than simply overpowering it.
How Hunger Circuits May Support Fat Loss
According to the researchers, the calorie deficit created during treatment appears to increase AgRP neuron activity, while those same neurons also contribute to the physiological changes that support fat loss. In other words, a neural population normally associated with the drive to restore lost calories may also participate in coordinating the body’s response to sustained weight reduction.
That could help explain why focusing only on how much a drug suppresses appetite gives an incomplete picture of obesity treatment.
What the Discovery Could Mean for Obesity Drugs
The findings do not mean that activating hunger neurons in people would necessarily improve weight loss. The experiments were performed in mice, and important questions remain about whether the same neural mechanism operates in humans.
The study also highlights how strongly biological context can influence a drug’s effects. In the mouse experiments, diet altered whether AgRP neurons were required for semaglutide-induced weight loss. That makes it difficult to reduce the drug’s action to a single brain pathway.
Identifying the circuits that help sustain weight loss could eventually matter for drug development. If researchers can separate the neural pathways responsible for durable fat loss from those responsible for unwanted effects, future treatments might be designed to produce stronger or more targeted metabolic benefits.
“By identifying a previously unrecognized neural mechanism involved in sustaining weight loss, our work provides new biological insights that could eventually help researchers design therapies that are even more effective or have fewer side effects,” d’Ávila said.
Reference: “AgRP neurons are required for the weight-lowering effects of GLP-1 receptor agonists in female mice” by Mateus d’Ávila, João Cavalcanti-de-Albuquerque, Roberto Collado-Pérez, Zhong-Wu Liu, Jenna Hunter, Anne White, Joseph Schlessinger, Giuseppe D’Agostino and Tamas L. Horvath, 4 August 2026, Proceedings of the National Academy of Sciences.
DOI: 10.1073/pnas.2614476123
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.
1 Comment
It’s also a huge step toward drugs with minimal side effects, because they are mimicing components of the body